N-pentylcyclopropanecarboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-pentylcyclopropanecarboxamide
• 化学式: C₉H₁₇NO
• 分子量: 155.24
• InChiKey: WFKRTDAQOAXJGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE
  申请人：Xi Ning

  公开号：US20100239576A1

  公开（公告）日：2010-09-23

  The present invention provides amino ester compounds, salts, and pharmaceutical formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

  本发明提供了氨基酯化合物、盐及其药物配方，用于调节蛋白酪氨酸激酶活性，以及调节细胞间和/或细胞内信号传导。该发明还提供了包含这些化合物的药用合适组合物，以及使用这些组合物治疗哺乳动物，特别是人类的增生性疾病的方法。
• [EN] PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS<br/>[FR] DERIVES DE PIPERAZINE FAISANT OFFICE D'ANTAGONISTES CCR5
  申请人：SCHERING CORP

  公开号：WO2000066558A1

  公开（公告）日：2000-11-09

  The use of CCR5 antagonists of formula (I) or a pharmaceutically acceptable salt thereof, wherein: R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R?4, R5 and R7¿ are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

  本发明涉及使用公式(I)的CCR5拮抗剂或其药学上可接受的盐，其中：R是可选的取代苯基、吡啶基、噻吩基或萘基；R1是氢或烷基；R2是取代苯基、取代杂环基、萘基、芴基、二苯甲基或可选取代的苯基或杂环基-烷基；R3是氢、烷基、烷氧基烷基、环烷基、环烷基烷基或可选取代的苯基、苯基烷基、萘基、萘基烷基、杂环基或杂环基烷基；R4、R5和R7是氢或烷基；R6是氢、烷基或烯基；用于治疗HIV、固体器官移植排斥、移植物对宿主病、关节炎、类风湿性关节炎、炎症性肠病、特应性皮炎、银屑病、哮喘、过敏或多发性硬化症，以及新的化合物、包含它们的药物组合物和本发明CCR5拮抗剂与用于治疗HIV或治疗炎症性疾病的药物的联合使用被揭示。
• Piperazine derivatives useful as CCR5 antagonists
  申请人：——

  公开号：US20030069252A1

  公开（公告）日：2003-04-10

  The use of CCR5 antagonists of the formula 1 or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R 1 is hydrogen or alkyl; R 2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R 3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R 4 , R 5 and R 7 are hydrogen or alkyl; R 6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

  本发明涉及CCR5拮抗剂的使用，其化学式为1或其药学上可接受的盐，其中R是可选取的取代苯基、吡啶基、噻吩基或萘基；R1是氢或烷基；R2是取代苯基、取代杂环芳基、萘基、芴基、二苯甲基或可选取代的苯基或杂环芳基烷基；R3是氢、烷基、烷氧基烷基、环烷基、环烷基烷基或可选取代的苯基、苯基烷基、萘基、萘基烷基、杂环芳基或杂环芳基烷基；R4、R5和R7是氢或烷基；R6是氢、烷基或烯烃基；用于治疗HIV、固体器官移植排斥、移植物抗宿主病、关节炎、类风湿性关节炎、炎症性肠病、特应性皮炎、银屑病、哮喘、过敏或多发性硬化症，还公开了新型化合物、包含它们的药物组合物以及本发明CCR5拮抗剂与抗HIV药物或治疗炎症性疾病的药物组合的组合物。
• PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS
  申请人：Baroudy Bahige M.

  公开号：US20080188485A1

  公开（公告）日：2008-08-07

  The use of CCR 5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R 1 is hydrogen or alkyl; R 2 is substituted phenyl, substituted heteroaryl, naphthyl fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroarylalkyl; R 3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R 4 , R 5 and R 7 are hydrogen or alkyl; R 6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

  本发明涉及CCR5拮抗剂的使用，其化学式为或其药学上可接受的盐，其中R是可选的取代苯基、吡啶基、噻吩基或萘基；R1是氢或烷基；R2是取代苯基、取代杂环芳基、萘基、芴基、二苯甲基或可选取代的苯基或杂环芳基烷基；R3是氢、烷基、烷氧基烷基、环烷基、环烷基烷基或可选取代的苯基、苯基烷基、萘基、萘基烷基、杂环芳基或杂环芳基烷基；R4、R5和R7是氢或烷基；R6是氢、烷基或烯基；用于治疗HIV、固体器官移植排斥、移植物抗宿主病、关节炎、类风湿性关节炎、炎症性肠病、特应性皮炎、牛皮癣、哮喘、过敏或多发性硬化症，以及新型化合物、包含它们的药物组合物，以及本发明的CCR5拮抗剂与用于治疗HIV或治疗炎症性疾病的抗病毒药物的组合。
• Tissue Factor Production Inhibitor
  申请人：Terasaka Naoki

  公开号：US20080255111A1

  公开（公告）日：2008-10-16

  A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.

  一种药物，具有抑制组织因子产生活性，包括LXR配体作为活性成分;以及用于治疗和/或预防血管再狭窄的药物，包括血管成形术，动脉内膜切除术，经皮冠状动脉成形术（PTCA）或支架植入术后的治疗和/或预防，或治疗和/或预防血液凝固疾病，包括稳定或不稳定的心绞痛，心血管和脑血管疾病，包括伴随糖尿病的血栓栓塞形成疾病，溶栓后再栓塞，脑缺血发作，梗塞，中风，缺血性痴呆，周围动脉疾病，主动脉冠状动脉旁路使用期间的血栓栓塞形成疾病，肾小球硬化，肾脏栓塞，肿瘤或癌症转移，其中包括LXR配体作为活性成分。